ASP Isotopes (NASDAQ:ASPI) Director Duncan Moore Sells 11,642 Shares

Key Points

• Director Duncan Moore sold 11,642 shares on April 16 at an average price of $5.21 for about $60,655, reducing his stake by 1.10% to 1,044,928 shares, as disclosed in an SEC filing.
• The company reported a quarterly loss of $0.84 per share versus a $0.14 consensus estimate (a notable EPS miss) despite reporting $33.32 million in revenue, and shows extreme negative profitability metrics (net margin -734.14%, ROE -307.82%).
• ASPI stock traded up 5.1% to $5.37 on heavy volume (7.36M shares vs. 4.53M avg), with a market cap around $676M, a 1-year range of $3.92–$14.49, mixed analyst ratings and a consensus target of $13.00; institutional investors own about 16.8% of the shares.

ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) Director Duncan Moore sold 11,642 shares of the stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $5.21, for a total transaction of $60,654.82. Following the transaction, the director owned 1,044,928 shares of the company's stock, valued at $5,444,074.88. The trade was a 1.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

ASP Isotopes Stock Up 5.1%

ASPI traded up $0.26 during trading hours on Friday, hitting $5.37. 7,361,541 shares of the company's stock were exchanged, compared to its average volume of 4,528,583. The stock has a market cap of $676.08 million, a price-to-earnings ratio of -2.51 and a beta of 3.59. ASP Isotopes Inc. has a 1-year low of $3.92 and a 1-year high of $14.49. The stock's 50-day moving average is $5.06 and its two-hundred day moving average is $6.73. The company has a quick ratio of 6.10, a current ratio of 6.14 and a debt-to-equity ratio of 1.04.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) last posted its quarterly earnings results on Friday, April 10th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.70). The company had revenue of $33.32 million for the quarter, compared to analyst estimates of $2.03 million. ASP Isotopes had a negative return on equity of 307.82% and a negative net margin of 734.14%. Sell-side analysts predict that ASP Isotopes Inc. will post -0.24 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on ASPI shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of ASP Isotopes in a research note on Friday, March 27th. Canaccord Genuity Group reiterated a "buy" rating and issued a $11.00 target price on shares of ASP Isotopes in a research note on Tuesday. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $13.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Quantbot Technologies LP acquired a new position in shares of ASP Isotopes during the 3rd quarter worth approximately $34,000. BNP Paribas Financial Markets raised its stake in ASP Isotopes by 84.9% in the second quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company's stock valued at $41,000 after purchasing an additional 2,548 shares in the last quarter. Close Asset Management Ltd acquired a new position in ASP Isotopes in the third quarter valued at about $72,000. Legal & General Group Plc raised its stake in ASP Isotopes by 30.4% in the third quarter. Legal & General Group Plc now owns 8,377 shares of the company's stock valued at $81,000 after purchasing an additional 1,953 shares in the last quarter. Finally, IFP Advisors Inc acquired a new position in ASP Isotopes in the fourth quarter valued at about $48,000. Institutional investors and hedge funds own 16.80% of the company's stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.